RejuvenAir Clinical Trial

The RejuvenAir System Trial for COPD with Chronic Bronchitis (SPRAY-CB) is currently recruiting patients in the United States. This trial is designed to continue to explore the safety and effectiveness of metered cryospray treatments in patients suffering from Chronic Bronchitis.

Image of AIRFLOW 3 Clinical Trial logo


The study purpose is Treatment.


Chronic Bronchitis is the largest disease subset of Chronic Obstructive Pulmonary Disease (COPD).
Unlike common Bronchitis, which is acute and clears up quickly, Chronic Bronchitis (CB) is characterized by a long-term productive cough, breathlessness and/or wheezing as well as a tight chest sensation.

The persistent cough itself can be debilitating. Patients with Chronic Bronchitis often avoid social situations and give up activities, further contributing to a decline in overall well-being and quality of life. While current medications help alleviate symptoms, they don’t address the underlying cause of the disease and are largely ineffective.

The RejuvenAir System is a revolutionary cryosurgical device which applies a precise thermal dose or “metered cryospray” of extremely cold, -196°C liquid nitrogen to targeted areas within the lungs through a minimally invasive, often outpatient or same-day bronchoscopic procedure.

RejuvenAir Metered Cryospray

Find out more information about this clinical trial and if you meet the requirements visit the RejuvenAir website.

Contact Us

For more information on this trial and to see if you qualify, please call us at 512-819-0132.